コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tumor sizes and spatial locations within the breast.
2 plemental screening test in women with dense breasts.
3 istribution and metabolites of As in broiler breasts.
4 R camera recorded IR images of the subject's breasts, a 3D scanner recorded surface geometries, and s
5 proving differential diagnosis of suspicious breast abnormalities and reducing unnecessary biopsies.
9 ogether, these results suggest patients with breast and other tumors characterized by PIK3CA C-termin
10 allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the fami
11 tivity of novel congeners in triple negative breast and ovarian cancers, malignancies that typically
12 thogenic variants associated with hereditary breast and/or ovarian cancer in two children, a likely p
13 smetic outcome and patient satisfaction with breast appearance were high with either no difference or
14 owever, incidental radiotracer uptake in the breasts can be observed in patients with nonbreast malig
16 en therapeutic advances; however, basal-like breast cancer (BLBC) remains clinically intractable.
18 oduli and mass of adherent colon (HT-29) and breast cancer (MCF-7) cells from the interphase through
19 ancer cells, including human triple-negative breast cancer (TNBC) and patient-derived TNBC cells in v
22 Treatment of patients with triple-negative breast cancer (TNBC) is limited by a lack of effective m
24 tance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer
25 py is yet available to treat triple negative breast cancer (TNBC), which has poor prognosis due to fr
27 ng the very aggressive human triple negative breast cancer (TNBC, MDA-MB-231 cells) growing in the br
31 pressive microenvironment of triple negative breast cancer and facilitate the checkpoint blockade imm
34 eceptor for lactate, which is upregulated in breast cancer and plays an autocrine role to promote tum
36 miological bidirectional association between breast cancer and schizophrenia may partly be explained
39 0-90(th) percentile) have a lifetime risk of breast cancer at 55% (95% CI 49-61%), which increases to
40 a prospective cohort of women diagnosed with breast cancer at age <= 40 years and enrolled patients b
43 can reduce tumor growth and invasiveness of breast cancer by noncanonical mechanisms unrelated to th
44 us was defined using age as a proxy, whereby breast cancer cases or deaths at age 50 years or older w
46 nase-targeted therapy in a subset of HER2(+) breast cancer cell lines and allow cancer cells to proli
47 binding with its promoter region in luminal breast cancer cell lines and indirectly through a distal
50 argeting miRNAs and examine their effects on breast cancer cell migration through exosome-mediated de
51 indicated that 8a decreases triple-negative breast cancer cell viability, and immunoblotting reveale
52 NA templates and validated with DNA from two breast cancer cell-lines and two patient tumour tissue s
54 ll-characterized cellular reference samples (breast cancer cells and B cells), captured either separa
55 latelets promote the metastasis of colon and breast cancer cells and suggests that GPVI represents a
56 the mesenchymal phenotype of triple-negative breast cancer cells and that CBFbeta-depleted cells unde
57 pe cells adopt MAPK-dependent circuitries in breast cancer cells and that the kinase TTK is important
58 oratories, we characterised a range of human breast cancer cells and their protein-level responses to
59 opy the PYCR1 knockdown in MCF10A H-RAS(V12) breast cancer cells by inhibiting de novo proline biosyn
64 e have employed varying EMT models of murine breast cancer cells to identify the key players establis
65 P followed by sequencing (ChIP-seq) in MCF-7 breast cancer cells treated with the proteasome inhibito
67 nvironments reminiscent of metastatic sites, breast cancer cells were more resistant to the estrogen
68 akdown and concomitant drug release, when in breast cancer cells with increased levels of reducing ag
69 ast array of long noncoding RNAs (lncRNA) in breast cancer cells, but their biological functions rema
70 haracterize effects of unacylated ghrelin on breast cancer cells, define its mechanism of action, and
71 rs distinct features to ER-negative DCIS.com breast cancer cells, leading to populations enriched wit
72 icinal plant Arabidopsis thaliana with human breast cancer cells, selectively suppresses cancer cell
75 tabolism has been unsuccessful so far in the breast cancer clinical setting, with major unresolved ch
77 Disparities in Outcomes Study, a prospective breast cancer cohort study, we implemented active mobile
78 t Cancer International Consortium (METABRIC) breast cancer cohort, FGFR4-induced and FGFR4-repressed
81 the estimated difference in 8-year risk for breast cancer death between continuing and stopping scre
82 digital breast tomosynthesis (DBT) improves breast cancer detection and recall rates compared with t
83 LIBRA measures on mammograms obtained before breast cancer diagnosis and compare their performance to
88 HDI) faced a greater burden of premenopausal breast cancer for both new cases and deaths compared wit
89 erapy was the standard treatment of advanced breast cancer for three decades until the discovery of t
90 opean ancestry diagnosed with first invasive breast cancer from 1990 onward with follow-up from the B
91 tudies provide insight into the landscape of breast cancer genomics with the genomic characterization
92 systems against malignant lung metastasis of breast cancer have been extensively studied, while metas
93 lanoma and other cancers, clinical trials in breast cancer have reported low responses to these thera
95 ed incidence rates (ASIRs) for premenopausal breast cancer in 20 of 44 populations and significantly
98 ogene and cooperate with HER2/neu to enhance breast cancer initiation and metastasis, despite having
104 uced small extracellular vesicles accelerate breast cancer metastasis, and targeted inhibition of tum
107 ibutions of pre- and post-EMT tumor cells in breast cancer metastasis.See related commentary by Bunz,
109 t result in substantial reductions in 8-year breast cancer mortality compared with stopping screening
113 one previous line of treatment for advanced breast cancer or relapsed within 12 months of neoadjuvan
114 ator of mammary epithelial proliferation and breast cancer pathogenesis likely via the modulation of
116 cal outcome in tamoxifen treated ER-positive breast cancer patients by repressing estrogen signaling
118 del to predict tumor response for two HER2 + breast cancer patients treated with the same therapeutic
120 MLK3 inhibitor in pan T cells, isolated from breast cancer patients, also increases cytotoxic CD8(+)
122 ssociated with better overall survival among breast cancer patients, while high fruit juice consumpti
127 igned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertu
129 doxorubicin-cyclophosphamide for stage I-III breast cancer received paclitaxel 175 mg/m(2) every 2 we
131 factor receptor 2 (HER2)-negative metastatic breast cancer represents a major milestone in cancer the
132 identified MD loci also are associated with breast cancer risk in an independent meta-analysis (P <
134 s Statement, we discuss the current state of breast cancer risk prediction, risk-stratified preventio
138 reatment of mice with disseminated ER+ human breast cancer showed that D9 plus MK-2206 blocked format
139 uggests the frequent coexistence of multiple breast cancer states within a PDTX model, the majority o
140 e citrullinating enzyme PADI4 in suppressing breast cancer stem cells through epigenetic repression o
146 Knowledge of fundamental differences between breast cancer subtypes has driven therapeutic advances;
148 higher double-positive signal in basal-like breast cancer than in luminal A or luminal B subtypes.
149 ty, and enabled the cellular architecture of breast cancer tissue to be characterized on the basis of
152 ically engineered orthotopic mouse models of breast cancer to show that while depletion of DeltaNp63
153 e 10-year cumulative IBTR incidence in early breast cancer treated with external APBI using IMRT tech
159 pausal women at increased risk of developing breast cancer were recruited and were randomly assigned
162 GWAS datasets suggested an increased risk of breast cancer with ERCC6 (main effect: 1.29 <= OR <= 2.9
163 -year-old woman with a previous diagnosis of breast cancer with liver metastasis presented with a com
164 factor receptor 2 (HER2)-negative metastatic breast cancer with prior clinical benefit from endocrine
166 to tumor-initiating cells in triple-negative breast cancer xenografts that rely on LEFTY1 for growth.
168 tologically confirmed advanced HER2-negative breast cancer, an Eastern Cooperative Oncology Group per
169 )F-ISO-1) to image solid tumors in lymphoma, breast cancer, and head and neck cancer has been previou
170 pes, including lymphoma, lung, glioblastoma, breast cancer, and several forms of leukemia, with prima
171 an elevated risk of developing contralateral breast cancer, and that the PRS can considerably improve
172 ncluded menopausal status, family history of breast cancer, body mass index, hormone replacement ther
175 d negative prognostic value in patients with breast cancer, inversely correlating with mitochondrial
176 BC), representing ~15% of globally diagnosed breast cancer, is typically an incurable malignancy due
178 rgeted therapy agents that are used to treat breast cancer, pancreatic cancer, colorectal cancer, or
180 ods: Five patients with a prior diagnosis of breast cancer, renal cell cancer, or leukemia underwent
181 s of EpCAM positive cancer cell lines (MCF-7 breast cancer, SW480 colon cancer, and PC3 prostate canc
183 endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered
185 otein expression in pre-treatment samples on breast cancer-specific and distant metastasis-free survi
209 studies are often performed in patients with breast cancer; however, incidental radiotracer uptake in
213 are detected at the invasive front of human breast cancers and independently predict metastatic rath
214 lly adopted strategy to treat colorectal and breast cancers as well as age-related macular degenerati
215 tMap by investigating the molecular basis of breast cancers capable of metastasizing to the brain-a p
217 t gene-environmental studies have focused on breast cancers generally, the preponderance of which occ
224 at TRIM21 enhances the proliferation of MCF7 breast carcinoma cells and counteracts the decrease in c
225 n the National Cancer Database with invasive breast carcinoma from 2012-2016 that underwent upfront l
226 for the transition from in situ to invasive breast carcinoma, and, accordingly, high EPN3 levels are
230 tory A 25-year-old woman was referred to our breast clinic for assessment of a palpable mass in her l
231 included patients age 18 years or older with breast, colon, or lung cancer who were prescribed cancer
232 nificantly associated with the risk of lung, breast, colorectal, or prostate cancers (OR range 0.78-1
233 the association between EGWG and daughters' breast composition (% of fibroglandular volume (%FGV) an
234 ns that were grossly examined at the time of breast conserving surgery from January 2014 to July 2020
235 l weight gain was self-reported in 2007, and breast density by digital mammography was measured in 20
237 RI tumor size>25mm, non-nodular enhancement, breast edema, areola-nipple complex retraction, and lymp
239 n have been shown to stimulate DNA damage in breast epithelial cells through mechanisms mediated by e
242 glish or Spanish, and had recently diagnosed breast, gastrointestinal, genitourinary, gynecological,
243 remaining 475 asymptomatic women with dense breasts had negative/benign DBT examinations before the
245 that yields high-quality diffusion-weighted breast images.Purpose: To compare multiplexed sensitivit
249 for future diagnostic assays for women with breast implants to distinguish seroma caused by BIA-ALCL
250 rwent high-resolution ultrasonography of the breast in addition to physical examination and mammograp
251 odifiable risk factor for cancer prevention (breast in particular), contributing to the current debat
252 For 13 of the 20 symptoms (abnormal mole, breast lump, post-menopausal bleeding, rectal bleeding,
253 tissues across seven cancer types, including breast, lung, ovary, pancreas, melanoma, bone, and brain
254 first clinical implementation of abbreviated breast magnetic resonance imaging (AB-MR) as a supplemen
255 n of malignant and benign lesions within the breast.Materials and Methods: In this prospective instit
256 ssary biopsies and rapid characterization of breast microcalcifications are unmet clinical needs.
258 n milk oligosaccharides (HMOs) and bioactive breast milk proteins have many beneficial properties.
259 the presence of Der p 1 and/or OVA in human breast milk, we identified groups of lactating mothers,
260 lergy, that is, D pteronyssinus allergens in breast milk, which disrupt gut immune homeostasis and pr
262 administration in breast screening.Keywords: Breast, MR-Diffusion Weighted Imaging, OncologySupplemen
263 US of the left breast (Fig 1), bilateral breast MRI (Fig 2), and fluorine 18 fluorodeoxyglucose P
264 a feasible and easily implementable routine breast MRI protocol that yields high-quality diffusion-w
265 patial-resolution technique that may enhance breast MRI protocols without the need for contrast mater
266 95.7% (95% CI, 79.0%-99.2%) with abbreviated breast MRI vs 39.1% (95% CI, 22.2%-59.2%) with DBT (P =
270 egative patients (cN0), 97.7% (432/442) with breast pCR had ypN0 compared with 71.6% (882/1232) witho
271 e-shot DWI sequences were first optimized in breast phantoms and then performed in a group of patient
272 gs that a once-weekly 5-fr schedule of whole-breast radiotherapy can be identified that appears to be
276 se of test set-based assessment schemes in a breast screening program has the potential to predict an
277 need for contrast material administration in breast screening.Keywords: Breast, MR-Diffusion Weighted
278 ormance in real life.(C) RSNA, 2020Keywords: Breast, ScreeningSee also the commentary by Thigpen and
280 e (PHTS) and are at high risk for developing breast, thyroid and other cancers and/or autoimmunity or
281 reached as high as 2.0E04 W/m(3) for normal breast tissue and ranged between 1.0E05-1.2E06 W/m(3) fo
283 a high-fat diet model of obesity in mice and breast tissue from women, we observed that TGFbeta1 acti
284 ic accuracy can be improved by assessing the breast tissue mechanical properties associated with path
285 ate results in measurable genomic changes in breast tissue with implications in breast carcinogenesis
295 gene expression analysis of matched primary breast tumours and bone metastasis-derived patient-deriv
296 esions classified as clustered microcysts at breast US were retrospectively identified in women at tw